Chronic 【Full Version】

On the health front, the FDA recently released a landmark draft guidance titled [1, 9]. This document aims to break the cycle of opioid reliance by accelerating the development of safer alternatives.

: In January 2025, the FDA approved Journavx (Suzetrigine) , the first non-opioid analgesic for moderate to severe acute pain, signaling a major step toward these new standards [33, 34]. Chronic

: The American Society of Anesthesiologists (ASA) reinforces the use of technique-based relief, such as fascial plane blocks, to reduce opioid needs after surgery [32]. On the health front, the FDA recently released

: Teams like the San Francisco 49ers are under increasing pressure to avoid these "painful draft memories" and find durable stars to replace an aging roster [29]. 2. FDA Draft Guidance: A New Era for Pain Management : The American Society of Anesthesiologists (ASA) reinforces

: Organizations like SIGN are also updating their recommendations to emphasize that opioids should not be routinely prescribed for chronic pain due to insufficient evidence of long-term benefit [27, 35]. Managing Life with Chronic Pain

: This follows a similar slide by 2025 prospect Will Johnson , who fell to the 47th pick over fears that chronic injuries would shorten his professional career [24].

: Experts at Dr. Vince Clinical Research note that the 2025 draft guidance introduces a flexible, mechanism-based framework. This allows drug developers to target shared pain pathways across multiple conditions rather than conducting duplicative trials for every specific ailment [2].